Human immunodeficiency virus type 1 disease progression, CCR5 genotype, and specific immune responses

Ubaldo Visco-Comandini, Catharina Hultgren, Christina Broström, Markus Birk, Soo Kim, Matti Sällberg

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The correlation among the presence of a 32-bp deletion in the CC-chemokine receptor 5 (CCR5) gene, disease progression, and human immunodeficiency virus type 1 (HIV-1)-specific immune responses was analyzed for a cohort of 79 Caucasian HIV-1-infected patients. The CCR5 genotype (CCR5/CCR5 = wild type/wild type or Δ32CCR5/CCR5 = 32-bp deletion/wild type) in peripheral blood mononuclear cells was determined by PCR, followed by sequencing of both wild-type and Δ32CCR5 gene fragments, HIV-1-specific humoral responses to gp41 and V3(MN) peptides were determined by enzyme immunoassays. The prevalence of the Δ32CCR5 allele was lower among 37 patients with rapid progression (progression to AIDS or to a CD4 cell count of 6/liter in less than 9 years; P <0.01) compared to that for 42 patients with slow progression (no AIDS and CD4 cell count of >200 x 106/liter after at least 9 years from infection) or to that for 25 non-HIV-1-infected Swedish blood donors (P <0.05). No differences were observed in the wild-type CCR5 sequences between the different groups of patients. For three analyzed patients, the 32-bp Δ32CCR5 gene deletions were identical. The antibody titers against gp41 and a V3(MN) peptide in patients with the Δ32CCR5/CCR5 genotype were not significantly different from those in pair-matched CCR5/CCR5 controls. However, in 13 analyzed patients, a stronger serum neutralizing activity was associated with the Δ32CCR5/CCR5 genotype. Thus, a CCR5/CCR5 genotype correlates with a shortened AIDS-free HIV-1 infection period and possibly with a worse neutralizing activity, without an evident influence on the antibody response to two major antigenic regions of HIV-1 envelope.

Original languageEnglish
Pages (from-to)463-466
Number of pages4
JournalClinical and Diagnostic Laboratory Immunology
Volume5
Issue number4
Publication statusPublished - 1998

Fingerprint

CCR5 Receptors
Virus Diseases
Viruses
Disease Progression
HIV-1
Genotype
Genes
Acquired Immunodeficiency Syndrome
Blood
Peptides
Antibodies
Gene Deletion
CD4 Lymphocyte Count
Blood Donors
Immunoenzyme Techniques
Antibody Formation

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Allergy
  • Clinical Biochemistry
  • Immunology

Cite this

Human immunodeficiency virus type 1 disease progression, CCR5 genotype, and specific immune responses. / Visco-Comandini, Ubaldo; Hultgren, Catharina; Broström, Christina; Birk, Markus; Kim, Soo; Sällberg, Matti.

In: Clinical and Diagnostic Laboratory Immunology, Vol. 5, No. 4, 1998, p. 463-466.

Research output: Contribution to journalArticle

Visco-Comandini, Ubaldo ; Hultgren, Catharina ; Broström, Christina ; Birk, Markus ; Kim, Soo ; Sällberg, Matti. / Human immunodeficiency virus type 1 disease progression, CCR5 genotype, and specific immune responses. In: Clinical and Diagnostic Laboratory Immunology. 1998 ; Vol. 5, No. 4. pp. 463-466.
@article{5e5c7531e5a64e36b4779719e660ce3d,
title = "Human immunodeficiency virus type 1 disease progression, CCR5 genotype, and specific immune responses",
abstract = "The correlation among the presence of a 32-bp deletion in the CC-chemokine receptor 5 (CCR5) gene, disease progression, and human immunodeficiency virus type 1 (HIV-1)-specific immune responses was analyzed for a cohort of 79 Caucasian HIV-1-infected patients. The CCR5 genotype (CCR5/CCR5 = wild type/wild type or Δ32CCR5/CCR5 = 32-bp deletion/wild type) in peripheral blood mononuclear cells was determined by PCR, followed by sequencing of both wild-type and Δ32CCR5 gene fragments, HIV-1-specific humoral responses to gp41 and V3(MN) peptides were determined by enzyme immunoassays. The prevalence of the Δ32CCR5 allele was lower among 37 patients with rapid progression (progression to AIDS or to a CD4 cell count of 6/liter in less than 9 years; P <0.01) compared to that for 42 patients with slow progression (no AIDS and CD4 cell count of >200 x 106/liter after at least 9 years from infection) or to that for 25 non-HIV-1-infected Swedish blood donors (P <0.05). No differences were observed in the wild-type CCR5 sequences between the different groups of patients. For three analyzed patients, the 32-bp Δ32CCR5 gene deletions were identical. The antibody titers against gp41 and a V3(MN) peptide in patients with the Δ32CCR5/CCR5 genotype were not significantly different from those in pair-matched CCR5/CCR5 controls. However, in 13 analyzed patients, a stronger serum neutralizing activity was associated with the Δ32CCR5/CCR5 genotype. Thus, a CCR5/CCR5 genotype correlates with a shortened AIDS-free HIV-1 infection period and possibly with a worse neutralizing activity, without an evident influence on the antibody response to two major antigenic regions of HIV-1 envelope.",
author = "Ubaldo Visco-Comandini and Catharina Hultgren and Christina Brostr{\"o}m and Markus Birk and Soo Kim and Matti S{\"a}llberg",
year = "1998",
language = "English",
volume = "5",
pages = "463--466",
journal = "Clinical and Diagnostic Laboratory Immunology",
issn = "1071-412X",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Human immunodeficiency virus type 1 disease progression, CCR5 genotype, and specific immune responses

AU - Visco-Comandini, Ubaldo

AU - Hultgren, Catharina

AU - Broström, Christina

AU - Birk, Markus

AU - Kim, Soo

AU - Sällberg, Matti

PY - 1998

Y1 - 1998

N2 - The correlation among the presence of a 32-bp deletion in the CC-chemokine receptor 5 (CCR5) gene, disease progression, and human immunodeficiency virus type 1 (HIV-1)-specific immune responses was analyzed for a cohort of 79 Caucasian HIV-1-infected patients. The CCR5 genotype (CCR5/CCR5 = wild type/wild type or Δ32CCR5/CCR5 = 32-bp deletion/wild type) in peripheral blood mononuclear cells was determined by PCR, followed by sequencing of both wild-type and Δ32CCR5 gene fragments, HIV-1-specific humoral responses to gp41 and V3(MN) peptides were determined by enzyme immunoassays. The prevalence of the Δ32CCR5 allele was lower among 37 patients with rapid progression (progression to AIDS or to a CD4 cell count of 6/liter in less than 9 years; P <0.01) compared to that for 42 patients with slow progression (no AIDS and CD4 cell count of >200 x 106/liter after at least 9 years from infection) or to that for 25 non-HIV-1-infected Swedish blood donors (P <0.05). No differences were observed in the wild-type CCR5 sequences between the different groups of patients. For three analyzed patients, the 32-bp Δ32CCR5 gene deletions were identical. The antibody titers against gp41 and a V3(MN) peptide in patients with the Δ32CCR5/CCR5 genotype were not significantly different from those in pair-matched CCR5/CCR5 controls. However, in 13 analyzed patients, a stronger serum neutralizing activity was associated with the Δ32CCR5/CCR5 genotype. Thus, a CCR5/CCR5 genotype correlates with a shortened AIDS-free HIV-1 infection period and possibly with a worse neutralizing activity, without an evident influence on the antibody response to two major antigenic regions of HIV-1 envelope.

AB - The correlation among the presence of a 32-bp deletion in the CC-chemokine receptor 5 (CCR5) gene, disease progression, and human immunodeficiency virus type 1 (HIV-1)-specific immune responses was analyzed for a cohort of 79 Caucasian HIV-1-infected patients. The CCR5 genotype (CCR5/CCR5 = wild type/wild type or Δ32CCR5/CCR5 = 32-bp deletion/wild type) in peripheral blood mononuclear cells was determined by PCR, followed by sequencing of both wild-type and Δ32CCR5 gene fragments, HIV-1-specific humoral responses to gp41 and V3(MN) peptides were determined by enzyme immunoassays. The prevalence of the Δ32CCR5 allele was lower among 37 patients with rapid progression (progression to AIDS or to a CD4 cell count of 6/liter in less than 9 years; P <0.01) compared to that for 42 patients with slow progression (no AIDS and CD4 cell count of >200 x 106/liter after at least 9 years from infection) or to that for 25 non-HIV-1-infected Swedish blood donors (P <0.05). No differences were observed in the wild-type CCR5 sequences between the different groups of patients. For three analyzed patients, the 32-bp Δ32CCR5 gene deletions were identical. The antibody titers against gp41 and a V3(MN) peptide in patients with the Δ32CCR5/CCR5 genotype were not significantly different from those in pair-matched CCR5/CCR5 controls. However, in 13 analyzed patients, a stronger serum neutralizing activity was associated with the Δ32CCR5/CCR5 genotype. Thus, a CCR5/CCR5 genotype correlates with a shortened AIDS-free HIV-1 infection period and possibly with a worse neutralizing activity, without an evident influence on the antibody response to two major antigenic regions of HIV-1 envelope.

UR - http://www.scopus.com/inward/record.url?scp=0031858846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031858846&partnerID=8YFLogxK

M3 - Article

C2 - 9665949

AN - SCOPUS:0031858846

VL - 5

SP - 463

EP - 466

JO - Clinical and Diagnostic Laboratory Immunology

JF - Clinical and Diagnostic Laboratory Immunology

SN - 1071-412X

IS - 4

ER -